Axsome Therapeutics' SWOT analysis: stock poised for growth amid CNS breakthroughs
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company has been gaining significant ...
Promising Outlook for Axsome Therapeutics Driven by Auvelity’s Strong Market Performance and Growth Prospects
Morgan Stanley analyst Vikram Purohit maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) yesterday and set a price target ...
Zacks.com on MSN6d
Axsome Shares Rise 19% in a Month: What's Driving the Rally?
AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while ...
Optimistic Buy Rating for Axsome Therapeutics Driven by Auvelity’s Strong Market Performance and Potential
Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on AXSM stock, giving a Buy rating on January 15.Invest with ...
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue
Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi ...
pharmaphorum6d
Axsome bounces back as FDA clears depression drug
Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...
Zacks.com on MSN16d
Axsome (AXSM) Moves 11.5% Higher: Will This Strength Last?
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in ...